GLP-1 Peptide Atlas, by Delfa

RecruitingPhase 1

A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity

Effect of Once-weekly Subcutaneous Administration of NNC0487-0111 on Energy Intake, Appetite and Postprandial Metabolism in Participants With Obesity - a Randomised, Placebo-controlled, Double Blinded Study

Lead sponsor

Novo Nordisk A/S

Asset

Amycretin / zenagamtide

Oral · GLP-1 / amylin

Listed sites

Recruiting sites

Enrollment

120

estimated

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Total energy intake across ad libitum breakfast, lunch, evening meal

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07508020

Org study IDNN9490-8151

Secondary ID2025-521393-34European Medicines Agency (EMA)

Secondary IDU1111-1319-9246World Health Organization (WHO)

Timeline

Milestones

Study start2026-03-30actual

Study first posted2026-04-02actual

Last update posted2026-04-27actual

Primary completion2028-01-19estimated

Study completion2028-01-22estimated

Assets

Investigational agents

Amycretin / zenagamtide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age64 Years

SexAll

Healthy volunteersNot accepted

Eligibility criteria

Key Inclusion Criteria:

•Male or female (sex at birth).

•Age 18-64 years (both inclusive) at the time of signing the informed consent.

•Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

•Overweight should be due to excess adipose tissue, as judged by the investigator.

Key Exclusion Criteria:

•Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.

•History of type 1 or type 2 diabetes mellitus.

•Glycated hemoglobin (HbA1c) ≥ 6.5 percent (%) (48 millimole per mole [mmol/mol]) at screening.

•Use of incretin or amylin-based therapies prior to screening or previous discontinuation of long-term incretin and/or amylin-based therapy due to tolerability issues.

•Any clinically significant body weight change (≥5 % self-reported change) or dieting attempts (e.g., participation in a weight reduction program) within 90 days before screening.

•Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions.

Endpoints (20)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Other (unclassified)

Weight & body composition

4 endpoints

Secondary/protocol endpoint

Relative change from Day 19 in body weight to Day 131

Time frame:From Day 19 to Day 131

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Relative change from Day 19 in body weight to Day 187

Time frame:From Day 19 to Day 187

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Relative change from Day 19 in body weight to Day 243

Time frame:From Day 19 to Day 243

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Relative change from Day 19 in body weight to Day 383

Time frame:From Day 19 to Day 383

Body weight, % change

percent change from baseline, improvement

Other clinical outcomes

11 endpoints

Primary/protocol endpoint/low confidence

Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 126

Time frame:From Baseline to Day 126

percent change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 126

Time frame:From Baseline to Day 126

change from baseline, improvement

Secondary/protocol endpoint

Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 182

Time frame:From Baseline to Day 182

change from baseline, improvement

Secondary/protocol endpoint

Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 126

Time frame:From Baseline to Day 126

change from baseline, improvement

Secondary/protocol endpoint

Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 182

Time frame:From Baseline to Day 182

change from baseline, improvement

Secondary/protocol endpoint

Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 238

Time frame:From Baseline to Day 238

change from baseline, improvement

Secondary/protocol endpoint

Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 378

Time frame:From Baseline to Day 378

percent change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change from baseline in total amount of food consumed during ad libitum breakfast, lunch, evening meal and snack box to Day 378

Time frame:From Baseline to Day 378

change from baseline, improvement

Secondary/protocol endpoint

Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 126

Time frame:From Baseline to Day 126

change from baseline, improvement

Secondary/protocol endpoint

Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 182

Time frame:From Baseline to Day 182

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 238

Time frame:From Baseline to Day 238

change from baseline, improvement

Other (unclassified)

5 endpoints

Primary/protocol endpoint/low confidence

Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 182

Time frame:From Baseline to Day 182

percent change from baseline, improvement

Primary/protocol endpoint/low confidence

Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 238

Time frame:From Baseline to Day 238

percent change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 238

Time frame:From Baseline to Day 238

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box at Day 378

Time frame:From Baseline to Day 378

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 378

Time frame:From Baseline to Day 378

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.